Last reviewed · How we verify

Vaxine Pty Ltd — Portfolio Competitive Intelligence Brief

Vaxine Pty Ltd pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
HBsAg HBsAg marketed Vaccine Hepatitis B surface antigen (HBsAg) Immunology / Infectious Disease
Recombinant influenza hemagglutinin Recombinant influenza hemagglutinin marketed Recombinant protein vaccine Influenza hemagglutinin Immunology / Infectious Disease
Commercial Hepatitis B vaccine Commercial Hepatitis B vaccine phase 3 Vaccine Hepatitis B surface antigen (HBsAg) Immunology
SpikoGen vaccine SpikoGen vaccine phase 3 Recombinant protein vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. GlaxoSmithKline · 2 shared drug classes
  3. Henogen · 2 shared drug classes
  4. Henry M. Jackson Foundation for the Advancement of Military Medicine · 2 shared drug classes
  5. Tan Tock Seng Hospital · 2 shared drug classes
  6. The University of Hong Kong · 2 shared drug classes
  7. BiondVax Pharmaceuticals ltd. · 1 shared drug class
  8. BioNTech · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vaxine Pty Ltd:

Cite this brief

Drug Landscape (2026). Vaxine Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vaxine-pty-ltd. Accessed 2026-06-10.

Related